Pretreatment Rostral Anterior Cingulate Cortex Theta Activity in Relation to Symptom Improvement in Depression

Pizzagalli, Diego A.; Webb, Christian A.; Dillon, Daniel G.; Tenke, Craig E.; Kayser, Jürgen; Goer, Franziska; Fava, Maurizio; McGrath, Patrick J.; Weissman, Myrna M.; Parsey, Ramin V.; Adams, Phil; Trombello, Joseph M.; Cooper, Crystal; Deldin, Patricia J.; Oquendo, María A.; McInnis, Melvin G.; Carmody, Thomas; Bruder, Gerard E.; Trivedi, Madhukar H.

doi:10.1001/jamapsychiatry.2018.0252

Cited by 162 publications

(142 citation statements)

References 58 publications

Supporting

Mentioning

131

Contrasting

Unclassified

Order By: Relevance

“…However, in the field of functional biomarkers, e.g. in neurophysiological research, several large studies have revealed meaningful patterns of ANS and CNS activity (Arns et al, 2015;Olbrich et al, 2016;Pizzagalli et al, 2018) that may inform the diagnostic process and the choice of treatment. The presented case now adds a possible marker for ERP treatment.…”

Section: Discussionmentioning

confidence: 99%

Exposure and response prevention therapy augmented with naltrexone in kleptomania: a controlled case study using galvanic skin response for monitoring

Olbrich

Jahn

Stengler

2019

Behav. Cogn. Psychother.

View full text Add to dashboard Cite

Background:Kleptomania is a disease that shares features with obsessive compulsive spectrum disorders (OCD) and with substance abuse disorders (SAD). This is underlined by therapeutic approaches in kleptomania ranging from cognitive behavioural therapy and selective serotonin reuptake inhibitors that are effective in OCD, and opioid antagonists that are currently being used in SAD. However, almost no literature exists about exposure and response prevention (ERP) therapy in kleptomania. Furthermore, there is a clear lack of objective markers that would allow a therapeutic monitoring.Aim:To show the effectiveness of ERP therapy in kleptomania in a single case report.Method:An ERP therapy under real-world conditions and later augmentation with the opioid antagonist naltrexone is described. Continuous measurements of galvanic skin response (GSR) before, during and after therapy sessions are reported in association with changes of the Kleptomania Symptom Assessment Scale (KSAS) self-questionnaire.Results:While KSAS scores showed a clear treatment response to ERP sessions, the GSR was significantly lower during ERP treatment in comparison with baseline measures. However, during augmentation with naltrexone, GSR measures increased again and clinical severity did not further improve.Conclusions:This case shows the possible usefulness of ERP-like approaches and therapy monitoring using electrophysiological markers of arousal for individualized treatment in kleptomania.

show abstract

Section: Discussionmentioning

confidence: 99%

Exposure and response prevention therapy augmented with naltrexone in kleptomania: a controlled case study using galvanic skin response for monitoring

Olbrich

Jahn

Stengler

2019

Behav. Cogn. Psychother.

View full text Add to dashboard Cite

show abstract

“…Nevertheless, more sophisticated analyses, such as theta-gamma phase-amplitude coupling (Sun et al, 2015;Noda et al, 2017), or dynamic causal modelling to determine changes in effective connectivity between brain regions (Lu et al, 2012;Harding et al, 2015;Breakspear, 2017), may reveal the effects of the intervention. For example, theta connectivity localised to the anterior cingulate cortex has been identified as a predictor of antidepressant response to treatment courses using transcranial magnetic stimulation (Narushima et al, 2010;Bailey et al, 2018), and sertraline (Pizzagalli et al, 2018).…”

Section: Discussionmentioning

confidence: 99%

Assessing neurophysiological changes associated with combined transcranial direct current stimulation and cognitive emotional training for treatment-resistant depression

Nikolin

Martin

Loo

et al. 2019

Preprint

View full text Add to dashboard Cite

Transcranial direct current stimulation (tDCS), a form of non-invasive brain stimulation, is a promising treatment for depression. Recent research suggests that tDCS efficacy can be augmented using concurrent cognitive emotional training (CET). However, the neurophysiological changes associated with this combined intervention remain to be elucidated. We therefore examined the effects of tDCS combined with CET using electroencephalography (EEG). A total of 20 participants with treatment resistant depression took part in this open-label study and received 18 sessions over 6 weeks of tDCS and concurrent CET. Resting-state and task-related EEG during a 3-back working memory task were aquired at baseline and immediately following the treatment course. Results showed an improvement in mood and working memory accuracy, but not response time, following the intervention. We did not find significant effects of the intervention on resting-state power spectral density (frontal theta and alpha asymmetry), time-frequency power (alpha eventrelated desynchronization and theta event-related synchronisation), or event-related potentials (P2 and P3 components). We therefore identified little evidence of neurophysiological changes associated with treatment using tDCS and concurrent CET, despite significant improvements in mood and near transfer effects of cognitive training to working memory accuracy. Further research incorporating a sham controlled group may be necessary to identify the neurophysiological effects of the intervention.

show abstract

“…At this point, probably the best supported candidate for a neuroimaging response biomarker is pgACC, with its increased activity being a predictor of good clinical response consistently shown over the past 20 years (e.g. [10,22,23]) and supported by meta-analyses and systematic reviews [19, 20••]. PgACC plays a crucial role in the development of depressive symptoms and antidepressant response due to its central position between the circuits responsible for a quick automatic response to emotionally salient stimuli and prefrontal regions exerting cognitive control over them.…”

Section: Pregenual Anterior Cingulate Cortex (Pgacc): a General Respomentioning

confidence: 99%

Neuroimaging as a Tool for Individualized Treatment Choice in Depression: the Past, the Present and the Future

Godlewska

2020

Curr Behav Neurosci Rep

View full text Add to dashboard Cite

Purpose of Review This paper aims to review the findings on neuroimaging as a tool for facilitating individualized treatment choice in depression. Recent Findings Neuroimaging has allowed the exploration of neural candidates for response biomarkers. In less than two decades, the field has expanded from small single drug studies to large multisite initiatives testing multiple interventions; from simple analytical methods to employing artificial intelligence, with an aim of establishing models based on a variety of data, such as neuroimaging, biological, psychological and clinical measures. Summary Neural biomarkers of response may play an important role in treatment response prediction. It seems likely that they will need to be considered together with other types of data in complex models in order to achieve the high accuracy and generalizability of results necessary for clinical use.

show abstract

Pretreatment Rostral Anterior Cingulate Cortex Theta Activity in Relation to Symptom Improvement in Depression

Abstract: clinicaltrials.gov Identifier: NCT01407094.

Cited by 162 publications

References 58 publications

Exposure and response prevention therapy augmented with naltrexone in kleptomania: a controlled case study using galvanic skin response for monitoring

Exposure and response prevention therapy augmented with naltrexone in kleptomania: a controlled case study using galvanic skin response for monitoring

Assessing neurophysiological changes associated with combined transcranial direct current stimulation and cognitive emotional training for treatment-resistant depression

Neuroimaging as a Tool for Individualized Treatment Choice in Depression: the Past, the Present and the Future

Contact Info

Product

Resources

About